logo
Search
Close this search box.
Schedule a Meeting
Search
Close this search box.
With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy
LEARN MORE

T2Bacteria and T2Candida are the first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample, independent of a positive blood culture.

T2Biothreat Panel: Now FDA-cleared
T2Biothreat has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)
LEARN MORE

The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx® Instrument and simultaneously detects six biothreat pathogens.

Enhancing the standard of care.

  • Reduce time to detection & species ID
  • Target therapy sooner
  • Reduce costs and length of stay
  • Enhance antimicrobial stewardship
  • Improve outcomes for patients
Learn More
With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2MR Technology

hospital-regular
UPMC
Demonstrated 47% reduction in antifungal therapy.
Learn More
hospital_icon
Henry Ford Health System
Realized 7 days reduction in median length of stay in the ICU.
Learn More
hospital_icon
Lee Health
T2Bacteria positive results 20 hours sooner than blood culture.
Learn More
hospital_icon
Huntsville Hospital
Saved ~$280 pharmacy costs per patient.
Learn More
hospital_icon
Robert Wood Johnson Medical School
Identified escalation and de-escalation opportunities in patients tested with T2Candida.
Learn More
hospital_icon
Riverside Community Hospital
100% of patients who tested positive received appropriate therapy in <9 hours
Learn More

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Avoidance of Inappropriate De-escalation with T2Candida

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

1 in 3
1 in 2-3
US hospital deaths.
11 million
deaths annually, worldwide.
Costs
$62 billion
in US healthcare costs.
Integrate T2 Biosystems panels into your hospital today!
Learn More

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2024 T2 Biosystems, Inc.

SITEMAP

FOLLOW US ON SOCIAL

Linkedin-in Twitter

Please tell us where you are visiting from: United States | Outside the United States